NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Long-term Follow up Local Registry Study of Kymriah in South Korea

RecruitingN/A

Sponsor: Novartis Pharmaceuticals

Conditions: B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma

Interventions: Tisagenlecleucel

Countries: South Korea

This study is multicenter, primary data collection, non-interventional registry study to assess long-term safety, secondary malignancy risk, and effectiveness of tisagenlecleucel in patients with B-cell malignancies in a routine clinical practice setting in Korea.

Eligibility overview

Sex: ALL

Age: 0 Years to 100 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Patients who receive tisagenlecleucel infusion in the commercial setting, treated under a managed access program or other pathway, e.g., when product was manufactured for the commercial setting but turned out to be out of specification (OOS).
2. Consented to data collection.

Exclusion Criteria:

1\. Patients who are enrolled or will be enrolled in the Novartis long term follow-up protocol CCTL019A2205B.

Locations (18)

Bundang Gu, Gyeonggi-do, South Korea
Seongnam-si, Gyeonggi-do, South Korea
Gyeonggi-do, Korea, South Korea
Incheon, Korea, South Korea
Seoul, Korea, South Korea
Seoul, Korea, South Korea
Seoul, Korea, South Korea
Seoul, Seoul, South Korea
Seoul, Seoul, South Korea
Seoul, Seoul, South Korea
Seoul, Yangcheon gu, South Korea
Busan, South Korea
Jeollanam, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Seoul, South Korea
Ulsan, South Korea